Skip to main content

Advertisement

Table 3 Phase 3 trials of tumor necrosis factor (TNF) inhibitors in nonradiographic spondyloarthritis and ankylosing spondylitis

From: Nonradiographic axial spondyloarthritis: clinical and therapeutic relevance

Trial TNF inhibitor Dose Primary endpoint Comparator Results
nr-axSpA Trials
 ABILITY-1 [27] Adalimumab 40 mg q 2 weeks ASAS40 response at week 12 Placebo ASAS20: 52% vs. 41% ASAS40: 36% vs. 15%
 RAPID-axSpA (nr-axSpA subset) [19] Certolizumab pegol 400 mg q 4 weeks ASAS20 response at week 12 Placebo ASAS20: 63% vs. 40% ASAS40: 47% vs. 16%
 EMBARK [51] Etanercept 50 mg q week ASAS40 response at week 12 Placebo ASAS20: 52% vs. 36% ASAS40: 33% vs. 15%
 GO-AHEAD [26] Golimumab 50 mg q 4 weeks ASAS20 response at week 16 Placebo ASAS20: 72% vs. 40% ASAS40: 57% vs. 23%
AS Trials
 ATLAS [56] Adalimumab 40 mg q 2 weeks ASAS20 response at week 12 Placebo ASAS20: 58% vs. 21% ASAS40: 40% vs. 13%
 RAPID-axSpA (AS subset) [19] Certolizumab pegol 400 mg q 4 weeks ASAS20 response at week 12 Placebo ASAS20: 64% vs. 37% ASAS40: 50% vs. 19%
 Etanercept phase III [57] Etanercept 50 mg q week ASAS20 response at week 12 Placebo ASAS20: 59% vs. 28% ASAS50: 44% vs. 16%
 GO-RAISE [53] Golimumab 50 mg q 4 weeks ASAS20 response at week 14 Placebo ASAS20: 59% vs. 22% ASAS40: 44% vs. 15%